Table 4. Adverse events of interest .... | American Society of Hematology

Table 4.

Adverse events of interest

	ZUMA-7		Belinda		Transform
	Axi-cel	SOC	Tisa-cel	SOC	Liso-cel	SOC
CRS, any grade (%)	92	—	61	—	49	—
CRS, grade ≥3 (%)	6	—	5	—	1	—
Neurologic toxicity, any grade (%)	60	—	10	—	12	—
Neurologic toxicity, grade ≥3 (%)	21	—	2	—	4	—
Tocilizumab use (%)	65	—	32	—	24	—
Corticosteroid usage for toxicity management (%)	24	—	10	—	17	—
Anemia, grade ≥3 (%)	30	39	33	58	49	49
Thrombocytopenia, grade ≥3 (%)	15	57	32	48	49	64
Neutropenia, grade ≥3 (%)	69	41	40	39	80	51
Febrile neutropenia, grade ≥3 (%)	2	27	13	25	15	24
Fatigue, any grade (%)	42	52	24	31	39	38
Nausea, any grade (%)	41	69	41	49	53	57

	ZUMA-7		Belinda		Transform
	Axi-cel	SOC	Tisa-cel	SOC	Liso-cel	SOC
CRS, any grade (%)	92	—	61	—	49	—
CRS, grade ≥3 (%)	6	—	5	—	1	—
Neurologic toxicity, any grade (%)	60	—	10	—	12	—
Neurologic toxicity, grade ≥3 (%)	21	—	2	—	4	—
Tocilizumab use (%)	65	—	32	—	24	—
Corticosteroid usage for toxicity management (%)	24	—	10	—	17	—
Anemia, grade ≥3 (%)	30	39	33	58	49	49
Thrombocytopenia, grade ≥3 (%)	15	57	32	48	49	64
Neutropenia, grade ≥3 (%)	69	41	40	39	80	51
Febrile neutropenia, grade ≥3 (%)	2	27	13	25	15	24
Fatigue, any grade (%)	42	52	24	31	39	38
Nausea, any grade (%)	41	69	41	49	53	57

SOC, standard of care.